TransMedics Group Inc (TMDX)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $3.17B
Last updated: Nov 17, 2026 at 11:06 AM ET
TransMedics Group Inc (TMDX) Financials: Revenue, Profit and Cash Flow
TransMedics Group reported revenue of $605.49M for the fiscal year ended Dec 31, 2025, up 37.1% from the year before. That year, net income was $190.29M with a net margin of 31.4%, operating cash flow was $192.84M and free cash flow was $133.59M. The quarter ended Sep 30, 2026 had revenue of $203.00M and net income of $17.07M.
Revenue and Margins
The operating margin was 17.9% in the fiscal year ended Dec 2025, the highest of the 4 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $6.21M, a compound annual rate of 66.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $605.49M | +37.1% | 59.9% | 17.9% | 31.4% |
| Dec 2024 | $441.54M | +82.7% | 59.4% | 8.5% | 8.0% |
| Dec 2023 | $241.62M | +158.5% | 63.8% | -11.9% | -10.4% |
| Dec 2022 | $93.46M | +208.8% | 69.8% | -33.6% | -38.8% |
| Dec 2021 | $30.26M | +18.0% | 69.9% | -130.3% | -146.1% |
| Dec 2020 | $25.64M | +8.6% | 64.9% | -102.9% | -112.1% |
| Dec 2019 | $23.60M | +81.3% | 58.7% | -125.4% | -142.1% |
| Dec 2018 | $13.02M | +69.4% | 44.1% | -155.5% | -182.5% |
| Dec 2017 | $7.68M | +23.8% | 27.8% | -265.8% | -271.0% |
| Dec 2016 | $6.21M | N/A | 12.3% | -370.2% | -387.6% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 436.6% from the year before. In the quarter ended Sep 2026, net income fell 29.8% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $605.49M | $441.54M | $241.62M | $93.46M | $30.26M | $25.64M | $23.60M | $13.02M | $7.68M | $6.21M |
| Cost of revenue | $242.69M | $179.46M | $87.53M | $28.19M | $9.10M | $9.00M | $9.74M | $7.28M | $5.55M | $5.44M |
| Gross profit | $362.81M | $262.08M | $154.09M | $65.27M | $21.16M | $16.64M | $13.86M | $5.73M | $2.14M | $766.00K |
| Research and development | $69.06M | $55.97M | $63.27M | $26.81M | $22.30M | $18.83M | $19.87M | $13.66M | $14.96M | $15.64M |
| Operating income | $108.58M | $37.50M | -$28.73M | -$31.44M | -$39.43M | -$26.38M | -$29.60M | -$20.24M | -$20.43M | -$22.99M |
| Net income | $190.29M | $35.46M | -$25.03M | -$36.23M | -$44.22M | -$28.75M | -$33.55M | -$23.76M | -$20.82M | -$24.07M |
| EBITDA | $148.49M | $69.95M | -$7.70M | -$28.58M | -$37.13M | -$22.52M | -$28.14M | -$20.23M | -$19.09M | -$22.66M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $203.00M | $189.95M | $173.93M | $160.76M | $143.82M | $157.37M | $143.54M | $121.62M | $108.76M | $114.31M | $96.85M | $81.17M |
| Gross profit | $118.66M | $113.20M | $101.16M | $93.41M | $84.58M | $96.59M | $88.23M | $72.01M | $60.84M | $69.26M | $59.96M | $47.92M |
| Operating income | $28.14M | $23.74M | $13.30M | $21.27M | $23.30M | $36.57M | $27.44M | $8.64M | $3.92M | $12.51M | $12.42M | $2.60M |
| Net income | $17.07M | $14.68M | $7.32M | $105.38M | $24.32M | $34.91M | $25.68M | $6.86M | $4.22M | $12.19M | $12.20M | $4.03M |
Balance Sheet
As of Dec 2025, total debt of $512.39M exceeded cash and equivalents by $24.02M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.07B | $804.08M | $706.05M | $277.15M | $134.89M | $152.03M | $105.30M | $42.16M | $37.00M | $58.10M |
| Current assets | $637.78M | $497.22M | $510.65M | $252.29M | $118.70M | $146.77M | $100.00M | $34.79M | $34.04M | $55.86M |
| Cash and equivalents | $488.37M | $336.65M | $394.81M | $201.18M | $25.58M | $24.58M | $20.09M | $20.24M | $11.94M | $9.84M |
| Total liabilities | $595.27M | $575.47M | $568.85M | $89.77M | $67.04M | $48.13M | $50.65M | $47.88M | $205.72M | $19.32M |
| Short-term debt | $10.00M | $0 | $2.04M | $1.44M | $8.60M | N/A | N/A | N/A | $1.80M | N/A |
| Long-term debt | $502.39M | $509.31M | $506.20M | $58.70M | $35.20M | $34.66M | $34.15M | $33.67M | $6.85M | $8.41M |
| Shareholder equity | $473.10M | $228.60M | $137.20M | $187.38M | $67.85M | $103.89M | $54.65M | -$192.24M | -$168.72M | $38.79M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.52B | $1.46B | $1.43B | $1.07B | $946.03M | $890.52M | $837.53M | $804.08M | $785.57M | $758.58M | $723.83M | $706.05M |
| Total liabilities | $967.23M | $946.34M | $940.81M | $595.27M | $590.83M | $572.42M | $571.22M | $575.47M | $575.65M | $568.68M | $564.36M | $568.85M |
| Cash and equivalents | $492.96M | $472.68M | $461.74M | $488.37M | $466.17M | $400.57M | $310.14M | $336.65M | $330.09M | $362.75M | $350.22M | $394.81M |
| Shareholder equity | $550.71M | $518.05M | $494.01M | $473.10M | $355.20M | $318.10M | $266.31M | $228.60M | $209.92M | $189.89M | $159.47M | $137.20M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 69.3% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $192.84M | $48.80M | -$13.03M | -$45.82M | -$28.86M | -$30.27M | -$32.29M | -$25.98M | -$23.10M | -$24.11M |
| Capital expenditures | $59.25M | $129.74M | $151.85M | $11.91M | $3.52M | $455.00K | $165.00K | $418.00K | $263.00K | $1.48M |
| Free cash flow | $133.59M | -$80.94M | -$164.88M | -$57.72M | -$32.38M | -$30.72M | -$32.45M | -$26.40M | -$23.36M | -$25.59M |
| Dividends paid | N/A | N/A | $51.12M | N/A | N/A | $357.00K | N/A | N/A | N/A | N/A |
| Share repurchases | N/A | N/A | N/A | $0 | $0 | $0 | $4.85M | N/A | N/A | N/A |
| Investing cash flow | -$59.25M | -$129.30M | -$193.95M | $54.51M | $29.27M | -$41.60M | -$60.50M | $12.31M | $24.86M | -$39.67M |
| Financing cash flow | $16.86M | $22.87M | $400.42M | $167.93M | $1.39M | $75.55M | $92.72M | $22.06M | $3.00K | $63.54M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $36.00M | $17.31M | $24.53M | $34.51M | $69.57M | $91.61M | -$2.85M | $19.66M | $6.86M | $25.72M | -$3.44M | $8.30M |
| Capital expenditures | $8.40M | $7.09M | $36.66M | $15.51M | $7.62M | $9.07M | $27.04M | $13.61M | $48.20M | $23.76M | $44.17M | $41.82M |
| Free cash flow | $27.60M | $10.22M | -$12.12M | $19.00M | $61.95M | $82.53M | -$29.89M | $6.06M | -$41.35M | $1.96M | -$47.61M | -$33.51M |
Frequently Asked Questions About TMDX
What is TransMedics Group's annual revenue?
TransMedics Group reported revenue of $605.49M for the fiscal year ended Dec 31, 2025.
How fast is TransMedics Group's revenue growing?
Revenue was up 37.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 86.4%.
Is TransMedics Group profitable?
Yes. TransMedics Group reported net income of $190.29M for the fiscal year ended Dec 31, 2025, with a net margin of 31.4%.
How much free cash flow does TMDX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $192.84M minus capital expenditures of $59.25M produced free cash flow of $133.59M.
How much debt does TransMedics Group have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $502.39M, short-term debt of $10.00M and cash and equivalents of $488.37M.
TMDX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors